*CE 0197
†The Atellica IM NfL assay, in conjunction with clinical, imaging, and laboratory findings, is intended to be used as an aid in identifying adult patients between 18–55 years of age with Relapsing Multiple Sclerosis (RMS), who are at a higher versus lower risk of MS disease activity, as defined by new or enlarging T2 (neT2) magnetic resonance imaging (MRI) lesions, within a 2 year period.